Advances in targeted therapies IV F C Breedveld, J R Kalden, and J S Smolen Ann Rheum Dis 2002; 61 (Supplement 2 ): 1. doi:10.1136/ard.61.suppl_2.ii1 [Extract] [Full text] [PDF] [Request Permissions]
	Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002) D E Furst, F C Breedveld, J R Kalden, J S Smolen, C E Antoni, J W J Bijlsma, G R Burmester, B Cronstein, E C Keystone, A Kavanaugh, and L Klareskog Ann Rheum Dis 2002; 61 (Supplement 2 ): 2. doi:10.1136/ard.61.suppl_2.ii2 [Extract] [Full text] [PDF] [Request Permissions]
	Subversion of the innate immune response by micro-organisms B Fernie-King, D J Seilly, A Davies, and P J Lachmann Ann Rheum Dis 2002; 61 (Supplement 2 ): 8. doi:10.1136/ard.61.suppl_2.ii8 [Extract] [Full text] [PDF] [Request Permissions]
	Is NF-B a useful therapeutic target in rheumatoid arthritis? M Feldmann, E Andreakos, C Smith, J Bondeson, S Yoshimura, S Kiriakidis, C Monaco, C Gasparini, S Sacre, A Lundberg, E Paleolog, N J Horwood, F M Brennan, and B M J Foxwell Ann Rheum Dis 2002; 61 (Supplement 2 ): 13. doi:10.1136/ard.61.suppl_2.ii13 [Abstract] [Full text] [PDF] [Request Permissions]
	Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis R Boismenu, Y Chen, K Chou, A El-Sheikh, and R Buelow Ann Rheum Dis 2002; 61 (Supplement 2 ): 19. doi:10.1136/ard.61.suppl_2.ii19 [Abstract] [Full text] [PDF] [Request Permissions]
	Balancing the immune system: Th1 and Th2 W van Eden, R van der Zee, P van Kooten, S E Berlo, P M Cobelens, A Kavelaars, C J Heijnen, B Prakken, S Roord, and S Albani Ann Rheum Dis 2002; 61 (Supplement 2 ): 25. doi:10.1136/ard.61.suppl_2.ii25 [Extract] [Full text] [PDF] [Request Permissions]
	Mesenchymal stem cells. A potential source for skeletal repair W E Fibbe Ann Rheum Dis 2002; 61 (Supplement 2 ): 29. doi:10.1136/ard.61.suppl_2.ii29 [Extract] [Full text] [PDF] [Request Permissions]
	Role of RANKL and RANK in bone loss and arthritis D Holstead Jones, Y-Y Kong, and J M Penninger Ann Rheum Dis 2002; 61 (Supplement 2 ): 32. doi:10.1136/ard.61.suppl_2.ii32 [Abstract] [Full text] [PDF] [Request Permissions]
	Functions of AP1 (Fos/Jun) in bone development E F Wagner Ann Rheum Dis 2002; 61 (Supplement 2 ): 40. doi:10.1136/ard.61.suppl_2.ii40 [Abstract] [Full text] [PDF] [Request Permissions]
	Treatments no longer in development for rheumatoid arthritis E Keystone Ann Rheum Dis 2002; 61 (Supplement 2 ): 43. doi:10.1136/ard.61.suppl_2.ii43 [Extract] [Full text] [PDF] [Request Permissions]
	Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis J E Salmon, G Girardi, and V M Holers Ann Rheum Dis 2002; 61 (Supplement 2 ): 46. doi:10.1136/ard.61.suppl_2.ii46 [Extract] [Full text] [PDF] [Request Permissions]
	Behçet’s disease: a new target for anti-tumour necrosis factor treatment P P Sfikakis Ann Rheum Dis 2002; 61 (Supplement 2 ): 51. doi:10.1136/ard.61.suppl_2.ii51 [Abstract] [Full text] [PDF] [Request Permissions]
	Protection against tuberculosis: cytokines, T cells, and macrophages S H E Kaufmann Ann Rheum Dis 2002; 61 (Supplement 2 ): 54. doi:10.1136/ard.61.suppl_2.ii54 [Abstract] [Full text] [PDF] [Request Permissions]
	Epidemiology, diagnostic possibilities, and treatment of tuberculosis R Kurth and W H Haas Ann Rheum Dis 2002; 61 (Supplement 2 ): 59. doi:10.1136/ard.61.suppl_2.ii59 [Extract] [Full text] [PDF] [Request Permissions]
	Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents D E Furst, J Cush, S Kaufmann, J Siegel, and R Kurth Ann Rheum Dis 2002; 61 (Supplement 2 ): 62. doi:10.1136/ard.61.suppl_2.ii62 [Extract] [Full text] [PDF] [Request Permissions]
	Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis V Strand, R Landéwé, and D van der Heijde Ann Rheum Dis 2002; 61 (Supplement 2 ): 64. doi:10.1136/ard.61.suppl_2.ii64 [Extract] [Full text] [Web only figure] [PDF] [Request Permissions]
	Infliximab treatment for rheumatic disease: clinical and radiological efficacy E W St Clair Ann Rheum Dis 2002; 61 (Supplement 2 ): 67. doi:10.1136/ard.61.suppl_2.ii67 [Abstract] [Full text] [PDF] [Request Permissions]
	Adalimumab (a fully human anti-tumour necrosis factor monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials R Rau Ann Rheum Dis 2002; 61 (Supplement 2 ): 70. doi:10.1136/ard.61.suppl_2.ii70 [Extract] [Full text] [PDF] [Request Permissions]
	Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis B Bresnihan Ann Rheum Dis 2002; 61 (Supplement 2 ): 74. doi:10.1136/ard.61.suppl_2.ii74 [Extract] [Full text] [PDF] [Request Permissions]
	Type II collagen degradation and its regulation in articular cartilage in osteoarthritis A R Poole, M Kobayashi, T Yasuda, S Laverty, F Mwale, T Kojima, T Sakai, C Wahl, S El-Maadawy, G Webb, E Tchetina, and W Wu Ann Rheum Dis 2002; 61 (Supplement 2 ): 78. doi:10.1136/ard.61.suppl_2.ii78 [Extract] [Full text] [PDF] [Request Permissions]
	Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis J Lam, Y Abu-Amer, C A Nelson, D H Fremont, F P Ross, and S L Teitelbaum Ann Rheum Dis 2002; 61 (Supplement 2 ): 82. doi:10.1136/ard.61.suppl_2.ii82 [Extract] [Full text] [PDF] [Request Permissions]
	Bone destruction in arthritis E M Gravallese Ann Rheum Dis 2002; 61 (Supplement 2 ): 84. doi:10.1136/ard.61.suppl_2.ii84 [Abstract] [Full text] [PDF] [Request Permissions]
	Cartilage destruction in rheumatoid arthritis S Gay, S Kuchen, R E Gay, and M Neidhart Ann Rheum Dis 2002; 61 (Supplement 2 ): 87. doi:10.1136/ard.61.suppl_2.ii87 [Extract] [Full text] [PDF] [Request Permissions]
	Pharmacovigilance: towards a better understanding of the benefit to risk ratio L S Simon Ann Rheum Dis 2002; 61 (Supplement 2 ): 88. doi:10.1136/ard.61.suppl_2.ii88 [Extract] [Full text] [PDF] [Request Permissions]
	Weight and consequences of post-marketing (-approval) experience G Kreutz Ann Rheum Dis 2002; 61 (Supplement 2 ): 90. doi:10.1136/ard.61.suppl_2.ii90 [Extract] [Full text] [PDF] [Request Permissions]
	The National Institute for Clinical Excellence (NICE) A-T Rodgers Ann Rheum Dis 2002; 61 (Supplement 2 ): 92. doi:10.1136/ard.61.suppl_2.ii92 [Extract] [Full text] [PDF] [Request Permissions]
	Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases R L Wilder Ann Rheum Dis 2002; 61 (Supplement 2 ): 96. doi:10.1136/ard.61.suppl_2.ii96 [Abstract] [Full text] [PDF] [Request Permissions]
	Role of interleukin 15 and interleukin 18 in inflammatory response F Y Liew and I B McInnes Ann Rheum Dis 2002; 61 (Supplement 2 ): 100. doi:10.1136/ard.61.suppl_2.ii100 [Abstract] [Full text] [PDF] [Request Permissions]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.